The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval
| Autor: | Andrei Iagaru, Guido Davidzon, Ryusuke Nakamoto, Judy Nguyen, Kip Guja, Farshad Moradi, Carina Mari Aparici, Hong Song, Benjamin L. Franc, Caitlyn Harrison, Negin Hatami |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Biochemical recurrence
Cancer Research PET-CT Prostatectomy business.industry medicine.medical_treatment Fda approval medicine.disease 030218 nuclear medicine & medical imaging Radiation therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine Oncology Cohort medicine Radiology Nuclear Medicine and imaging Recurrent prostate cancer business Nuclear medicine |
| Zdroj: | Molecular Imaging and Biology. 23:614-623 |
| ISSN: | 1860-2002 1536-1632 |
| DOI: | 10.1007/s11307-021-01583-3 |
| Popis: | To evaluate the diagnostic performance and clinical utility of 18F-fluciclovine PET/CT in patients with biochemical recurrence (BCR) of prostate cancer (PC). 18F-Fluciclovine scans of 165 consecutive men with BCR after primary definitive treatment with prostatectomy (n = 102) or radiotherapy (n = 63) were retrospectively evaluated. Seventy patients had concurrent imaging with at least one other conventional modality (CT (n = 31), MRI (n = 31), or bone scan (n = 26)). Findings from 18F-fluciclovine PET were compared with those from conventional imaging modalities. The positivity rate and impact of 18F-fluciclovine PET on patient management were recorded. In 33 patients who underwent at least one other PET imaging (18F-NaF PET/CT (n = 12), 68Ga-PSMA11 PET/CT (n = 5), 18F-DCFPyL PET/CT (n = 20), and 68Ga-RM2 PET/MRI (n = 5)), additional findings were evaluated. The overall positivity rate of 18F-fluciclovine PET was 67 %, which, as expected, increased with higher prostate-specific antigen (PSA) levels (ng/ml): 15 % (PSA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink